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ABSTRACT
Purpose: We have previously shown that supraoptimal signaling of high avidity 
T cells leads to high expression of PD-1 and inhibition of proliferation. This study was 
designed to see if this effect could be mitigated by combining a vaccine that stimulates 
high avidity T cells with PD-1 blockade.
Experimental Design: We investigated the anti-tumor effect of a huIgG1 antibody 
DNA vaccine (SCIB1) and PD-1 blockade.
Results: Vaccination of HLA-DR4 transgenic mice with SCIB1 induced high 
frequency and avidity T cell responses that resulted in survival (40%) of mice with 
established B16F1-DR4 tumors. SCIB1 vaccination was associated with increased 
infiltration of CD4 and CD8 T cells within the tumor but was also associated with 
upregulation of PD-L1 within the tumor environment. PD-1 blockade also resulted in 
increased CD8 T cell infiltration and an anti-tumor response with 50% of mice showing 
long term survival.In line with our hypothesis that PD-1/PD-L1 signaling results in 
inhibition of proliferation of high avidity T cells at the tumor site, the combination of 
PD-1 blockade with vaccination, enhanced the number and proliferation of the CD8 
tumor infiltrate. This resulted in a potent anti-tumor response with 80% survival of 
the mice.
Conclusions: There is a benefit in combining PD-1 blockade with vaccines that 
induce high avidity T cell responses and in particular with SCIB1.
INTRODUCTION
Numerous studies have shown that PD-1/PD-
L1 pathway is a negative regulator of T cells and that 
blocking this pathway can lead to improved T cell 
immunity [1, 2]. Two anti-PD-1 mAbs, Nivolumab and 
Pembrolizumab have been approved for the treatment 
of cancer. Nivolumab induces an objective response rate 
(ORR) of 30-40% in multiple clinical trials in patients 
with melanoma [3, 4], it extends overall survival in Non-
Small-Cell lung cancer [5, 6] and produces an ORR of as 
high as 87% in Hodgkin’s lymphoma [7]. Pembrolizumab 
has improved efficacy over Ipilimumab [8] and is now 
approved second line treatment for melanoma. It is also 
showing encouraging results in NSCLC [9], gastric 
cancer [10], bladder cancer [11], head and neck cancer 
[12], Hodgkin’s lymphoma [13] and triple negative breast 
cancer [14]. Although there is evidence that patients whose 
tumors express PD-L1 have a higher response rate, many 
PD-L1 negative patients also respond. This discrepancy 
may be related to “adaptive resistance” which stems 
from the observation that normal cells and most cell lines 
do not express PD-L1 unless it is induced by IFNγ. As 
this cytokine is predominantly secreted by lymphocytes 
the adaptive theory suggests that tumors are induced to 
express PD-L1 by tumor infiltrating lymphocytes as 
a method to limit tissue damage but would also serve 
to suppress tumor immunity [1]. Thus blockade of the 
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PD-1/PD-L1 interaction will enhance T cell responses 
at the tumor site thus restricting toxicity. Despite these 
encouraging responses the majority of patients do not 
respond to PD-1/PD-L1 blockade. This may be related to 
the inability of the tumor to stimulate a productive T cell 
response. Recent studies have suggested that this may be 
related to the number and/or type of mutations within a 
tumor which can lead to neo-epitopes [15]. However, non-
responders may not have the appropriate mutations and/or 
fail to stimulate a productive immune response [15, 16]. 
These patients may benefit from an effective vaccine that 
stimulates de novo high avidity CD4 and CD8 responses 
prior to checkpoint blockade.
We have previously shown that immunizing with 
a DNA vaccine incorporating CD8 and CD4 T cell 
epitopes within an antibody framework (ImmunoBody®) 
without any additional adjuvants stimulates high 
frequency, high avidity responses to a wide range of 
epitopes [17, 18]. The ImmunoBody® acts by direct 
presentation of the DNA within antigen presenting cells 
and cross-presentation of secreted protein via the high 
affinity FcγR1 receptor (CD64). When comparing DNA 
and protein immunization of ImmunoBody®, the DNA 
gave higher frequency and avidity responses suggesting 
direct presentation of the DNA within antigen presenting 
cells. However, experiments in CD64 knockout mice 
but not CD32 knockout mice, induced lower frequency 
and avidity T responses in wild type mice suggesting 
that cross-presentation of secreted protein via the 
high affinity FcγR1 receptor (CD64) was important. 
Although either presentation induces T cell responses, 
it is only the combination that induces T cells with 
sufficiently high avidity to kill tumor cells [17, 18]. 
This was further validated by comparison of the same 
ImmunoBody® DNA expressing Fab or whole antibody 
molecules, which showed much weaker responses in the 
absence of Fc. We have also replaced human IgG1 from 
the same DNA backbone vector with moIgG2a, both 
huIgG1 and moIgG2a can stimulate immune responses 
in mice [17]. SCIB1 is an ImmunoBody® encoding a 
human IgG1 antibody, with three epitopes from gp100 
and one from TRP-2 engineered into its CDR regions. 
There are two HLA*0201 epitopes, one from TRP-
2180-188 (SVYDFFVWL) which also is H-2Kb restricted 
and one from gp100178-186 (MLGTHTMEV), and two 
CD4 epitopes one is HLA-DR4 restricted gp10044-59 
epitope (WNRQLYPEWTEAQRLD) and the other 
gp100174-190 epitope (TGRAMLGTHTMEVTVYH) 
restricted by HLA-DR7, HLA-DR53 and HLA-
DQ6. We have previously shown that the TRP-2 CD8 
epitope breaks tolerance and induces high avidity T 
cell memory responses to this self-epitope [18]. In this 
study we show that the gp100DR4 epitope stimulates 
strong CD4 T cells responses which is consistent with 
previous publications [17]. A clinical study in stage 
III/IV melanoma patients with tumor present at study 
entry showed that SCIB1 could induce T cell responses 
in 10/11 patients to all 4 encoded epitopes with no 
associated toxicity. Overall survival was 19 months with 
patients showing clinical responses including two partial 
responses and stable disease. Results were even more 
dramatic in patients with fully resected disease as they 
all showed a T cell response and are still alive with 
a current median observation time of 3 years. Two- and 
three-year recurrence-free survival for stage III resected 
patients was 89% and 67%, respectively, and for stage 
IV resected patients it was 71% at both time points [19].
We have shown that potent high avidity T cells 
induced by SCIB1 express high levels of PD-1 and are 
susceptible to growth inhibition and apoptosis [20]. If 
this occurs within the tumor microenvironment due to 
“adaptive resistance” then a combination of SCIB1 and 
anti-PD-1 may lead to clinical benefit. We have tested 
this hypothesis in the poorly immunogenic B16F1-DR4 
model using the SCIB1 vaccine. In this study we show that 
SCIB1 provides efficient tumor therapy in 40% of animals. 
This can be further enhanced by combination with PD-1 
blockade where the therapy promotes proliferation of CD8 
T cells within the tumor microenvironment resulting in 
significantly longer survival in animals than either vaccine 
or PD-1 blockade alone.
RESULTS
Combined SCIB1 and PD-1 blockade induced a 
strong anti-tumor response
We have previously shown that insertion of 
CD8 epitopes TRP2 (aa180-188) and CD4 epitopes 
from gp100 (aa44-59 and 174-190) into human IgG1 
antibody DNA vaccine (SCIB1) induces high frequency 
and avidity CD8 and CD4 T cell responses in mice [17] 
and melanoma patients [19]. In this study, we show that 
these immune responses result in therapeutic anti-tumor 
responses against established B16F1-DR4 tumors and 
in long term survival in 40% of mice (p=0.022, Figure 
1A). A similar anti-tumor response can be induced by 
PD-1 blockade which resulted in long term survival in 
50% of mice (p= 0.0047, Figure 1A). This anti-tumor 
response could be significantly enhanced by combining 
PD-1 blockade with SCIB1 showing enhanced survival of 
80% compared to control (p<0.0001) or when compared 
to SCIB1 (p=0.0066) or PD-1 blockade alone (p=0.0234) 
(Figure 1A). Figure 1B shows growth of tumors was 
significantly delayed compared to control when mice 
were treated with SCIB1 (p=0.023) or SCIB1 combined 
with PD-1 blockade (p=0.0032). To further investigate the 
efficacy of combination vaccine, the mice were challenged 
with a higher dose of B16F1-DR4 tumor cells (1.5x105). 
Only combination therapy demonstrates a significant 
survival advantage over control (Control vs SCIB1+PD-1 
p=0.0126) (Figure 1C).
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SCIB1 induces stronger tumor specific CD8 and 
CD4 responses than tumor cells whilst anti-PD-1 
stimulates a different repertoire
SCIB1 vaccine encodes epitopes from melanoma 
antigens TRP2 and gp100 which are also present in 
B16F1-DR4 tumor. The tumor has the potential to 
stimulate these specific immune responses so analysis 
was performed to compare the epitope specific immune 
responses induced by SCIB1 and tumor cells. In 
HLA-DR4 transgenic mice, SCIB1 induces higher 
frequency TRP2180-188 and gp10044-59 epitope specific 
responses compared to those induced by HLA-DR4 
expressing B16 tumor cells (p=0.0002) (Figure 2A). 
Analysis of the avidity of the responses show that 
SCIB1 induces higher avidity TRP2 specific responses 
than those induced by the tumor cells suggesting that 
tumor provides insufficient stimulation and promotes 
a weak autoimmune response (Figure 2B). In contrast, 
both SCIB1 and the tumor induce similar avidity CD4 
responses (Figure 2C).
To further understand why PD-1 treatment alone 
induces anti-tumor responses in our model, we examined its 
effect on in vitro tumor recognition. Interestingly, addition 
of PD-1 antibody to tumor induced immune responses 
stimulated better tumor recognition than that seen with 
immunization with tumor only (Figure 2D). However, the 
PD-1 blockade did not enhance TRP2 or gp100 specific 
responses which suggests that PD-1 blockade enhanced 
responses to tumor epitopes other than TRP2 and gp100.
Tumor and PD-1 blockade did not influence 
systemic SCIB1 or tumor induced immune 
responses
Studies examining the adoptive transfer of tumor 
reactive T cells have demonstrated the induction of 
exhaustion/tolerance by the tumor. We next sought to 
determine the effect of tumor on the induction of tumor 
antigen specific responses in the spleen by SCIB1 and 
SCIB1 plus PD-1 blockade. Immunization of HLA-DR4 
transgenic mice revealed that even in the presence of tumor, 
Figure 1: Combination of SCIB1 with PD-1 blockade enhances tumor therapy. Mice were challenged with 2.5x104 B16F1-
DR4 tumor and immunized with SCIB1, anti-PD-1 antibody or the combination were assessed for A. Survival and B. Average tumor 
growth over time. C. Survival of mice challenged with 1.5x105 B16F1-DR4 tumors and immunized with SCIB1, anti-PD-1 antibody or the 
combination. (*, P<0.05; **, P<0.01; ***, P<0.001). Each curve details results from a representative of at least two independent studies 
with at least 10 mice per group.
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SCIB1 still generates high frequency and avidity CD8 and 
CD4 T cell responses (Figure 3A and 3B). Addition of PD-1 
blockade did not alter the frequency or the avidity of the 
T cell responses induced by vaccination in the presence 
of tumor suggesting that blockade of PD-1 pathway does 
not have direct effect on T cell responses generated by 
SCIB1 (Figure 3A, 3B and 3C). PD-1 blockade also did 
not significantly enhance the weak CD8 and CD4 responses 
generated by tumor itself (Figure 3A, 3B and 3C).
Combined SCIB1 and PD-1 blockade increased 
CD8 and CD4 T cells within the tumor 
microenvironment
To further understand the mechanism underlying 
the strong additive anti-tumor responses, the effects 
of each treatment on tumor infiltrating lymphocytes 
was examined. The number of total CD45+ leukocytes 
was markedly increased following SCIB1 (p=0.0192) 
and SCIB1 plus PD-1 blockade (p=0.0024) treatment 
(Figure 4A). The number of CD3+CD8+ cells was 
increased 3 fold by SCIB1 vaccination (p=0.0157) 
and was further enhanced 10 fold by the addition of 
PD-1 blockade (p=0.0468) (Figure 4B). When gated on 
CD45+ population, a similar trend in percentage of CD8 
infiltration was seen (Figure 4C). PD-1 blockade alone 
appeared to have a small effect on the percentage CD8 
T cell infiltration (p=0.05). The combination vaccine 
further enhanced CD8 T cells infiltration over PD-1 alone 
(p=0.0026) or SCIB1 alone (p=0.0004) (Figure 4C). Both 
SCIB1 alone (p=0.0086) and addition of PD-1 blockade to 
SCIB1 (p=0.0321) significantly increased the percentage 
Figure 2: SCIB1 immunization induces better responses compared to tumor. A. Splenocytes from SCIB1 or tumor immunized 
mice were analyzed by IFNγ elispot assay for frequency of peptide specific responses. Avidity of responses was measured to increasing 
TRP2 B. or gp10044-59 C. peptide concentrations. Normalized avidity graphs are shown. D. Splenocytes from mice immunized with tumor 
in the presence or absence of anti-PD-1 Ab were analyzed by IFNγ elispot assay for tumor recognition and frequency of peptide specific 
responses. Results are representative of at least two independent studies where n≥3. (*, P<0.05; **, P<0.01; ***, P<0.001).
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of CD4 T cells infiltrating the tumor site compared to 
control (Figure 4D). This suggests that SCIB1 alone 
and in combination with PD-1 blockade enhances CD8 
and CD4 T cell infiltrate into the tumor environment. In 
contrast, the treatments induced no significant differences 
in the number of infiltrating Foxp3 expressing regulatory 
CD4 T cells in the tumors (Figure 4E). Both SCIB1 and 
SCIB1 plus PD-1 blockade reduced the number of MDSC 
(CD11b+GR1hi+) infiltrating into the tumors but this did 
not reach significance (Figure 4F).
PD-1 blockade enhances CD8 T cell proliferation 
but not T cell migration from the lymph node
Since combined therapy showed a strong anti-
tumor effect and increased T cell infiltration, we sought 
to determine if it was a result of further T cell migration 
from lymph nodes or protection of T cells already at 
the tumor site. Previous studies showed treatment with 
FTY720, an immunomodulatory drug, blocks sphingosine 
1-phosphate receptors and inhibits T cell migration from 
lymphoid organs [21, 22]. We therefore utilized it in our 
anti-tumor model in combination with SCIB1 or SCIB1 
plus PD-1 therapy to assess its effect on tumor therapy and 
T cell infiltration. We showed FTY720 effectively reduced 
survival of SCIB1 or SCIB1 plus PD-1 treated groups (P= 
0.001; P= 0.0387 respectively; Figure 5A). Analysis of T 
cell infiltration showed that FTY720 completely blocked 
the increase in CD8 and CD4 T cell infiltration at tumor 
site seen with SCIB1 vaccination (Figure 5B and 5C). 
FTY720 treatment also showed a reduction in T cell 
infiltrate into tumors in SCIB1 plus PD-1 treated mice. 
Interestingly, there is a significant difference between 
FTY720 treated SCIB1 and FTY720 treated SCIB1 plus 
PD-1 for both CD8 and CD4 infiltration (P=0.0096; 
P=0.0154) (Figure 5B and 5C). Thus it suggests that 
although FTY720 could significantly reduce T cell 
migration into the tumor site induced by SCIB1, PD-1 
blockade could still protect the remaining T cells within 
the tumor resulting in enhanced survival.
T cell proliferation was determined by analyzing 
Ki67 expression on tumor infiltrating CD8 and CD4 T cells 
(Figure 5D and 5E). SCIB1 alone (p=0.0188) and PD-1 
blockade alone (p=0.0441) showed significant increase in 
Figure 3: Addition of PD-1 blockade to SCIB1 did not further enhance the immune responses generated in the 
presence of tumor. Mice were implanted with tumor and subsequently vaccinated with SCIB1, PD-1 blockade or combination vaccine. 
A. Splenocytes were assessed by IFNγ elispot assay for frequency of peptide specific responses. Avidity of responses was measured to 
increasing B. TRP2 or C. gp10044-59 peptide concentrations. Normalized avidity graph is shown. Results are representative of at least two 
independent studies where n≥3.
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Figure 4: Combination of SCIB1 vaccine with PD-1 blockade increases T cell infiltrate into tumors. Tumors from untreated 
mice or those treated with SCIB1, PD-1 blockade or the combination were assessed for A. Number of CD45+ T cell infiltrate per million 
tumor cells; B. Number of CD8+ T cell infiltrate per million tumor cells; C. CD3+CD8+ T cell infiltrate as a % of CD45+; D. CD3+CD4+ 
T cell infiltrate as a % of CD45+; E. Treg (CD4+FoxP3+) infiltrate as a % of CD45+CD3+; F. MDSC (CD11b+GR1hi+) infiltrate as a % 
of CD45+. Analysis of (A) and (B) is gated on the whole tumor cell population. Analysis of (C-F) is gated on CD45+ population while 
(E) is gated on CD45+CD3+ population (*, P<0.05; **, P<0.01; ***, P<0.001; **** p<0.0001). Results are a combined from at least 2 
independent studies in which n≥5.
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Figure 5: PD-1 blockade enhances CD8 T cell proliferation but not T cell migration from the lymph node. Mice were 
challenged with 1x105 B16F1-DR4 tumor cells and immunized with SCIB1 or combination vaccine in the presence and absence of FTY720 
were assessed for A. survival, B. CD8+ infiltrating T cells, C. CD4+ infiltrating T cells. Analysis of (B and C) is gated on CD45+ population. 
Tumor-infiltrating lymphocytes from mice immunized with SCIB1, PD-1 blockade or combination were assessed for D. Ki67 expression 
on CD8+ T cells and E. Ki67 expression on CD4+ T cells. Analysis of (D and E) is gated on CD45+CD3+ population. Results from a 
representative study with at least 10 mice per group, B-E show combined data from at least 2 independent studies (*, P<0.05; **, P<0.01; 
***, P<0.001; ****, p<0.0001).
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the number of CD8 T cells expressing Ki67 compared to 
control (Figure 5D). Addition of PD-1 blockade to SCIB1 
resulted in a further increase in the number of CD8 T cells 
expressing Ki67 compared to SCIB1 alone (p=0.0373) or 
PD-1 blockade alone (p=0.0176). There is a small increase 
in Ki67 expression on CD4 T cells from SCIB1 alone and 
combination groups (Figure 5E).
Adaptive resistance
PD-L1 is induced on tumor cells by tumor infiltrating 
lymphocytes releasing IFNγ as a method to limit tissue 
damage but which also restricts tumor immunotherapy. To 
determine if the infiltrating lymphocytes were secreting 
IFNγ, they were isolated and stimulated overnight with 
anti-CD3 antibody. As demonstrated in Figure 6A, CD3 
stimulation results in the production of IFNγ in both 
SCIB1 alone and combination vaccine groups which are 
significantly higher than control (p=0.0001, p<0.0001, 
respectively) and anti-PD-1 alone (p<0.0001; p<0.0001, 
respectively) treated mice. Of particular interest was 
the low levels of IFNγ produced in the anti-PD-1 alone 
treated mice, even though they showed a good anti-
tumor response. As functional TILs secreting IFNγ 
Figure 6: Analysis of TIL function and PD-L1 expression on tumor in mice immunized with single or combination 
vaccines. A. TILs from mice immunized with SCIB1, PD-1 blockade or combination were assessed for IFNγ release in response to anti-
CD3 stimulation measured by ELISA. Results are combined data from at least two independent studies where n≥5 (***, P<0.001; ****, 
p<0.0001). B. PD-L1 expression within tumor environment where analysis is gated on whole tumor sample and shows representative data 
n≥3.
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could potentially upregulate PDL-1 expression within 
the tumor microenvironment, levels of PD-L1 on tumors 
were assessed. In agreement with the TIL results, SCIB1 
alone and the combination vaccine upregulated PD-L1 
expression whereas control and PD-1 blockade alone did 
not (Figure 6B).
DISCUSSION
In this study we demonstrate the efficient induction 
of high frequency and avidity melanoma antigen specific 
CD8 and CD4 responses from SCIB1 DNA vaccine. These 
responses provide tumor therapy in the aggressive murine 
B16 melanoma model. Thus, suggesting that the high 
avidity T cell responses, generated by SCIB1 vaccination, 
where more effective in tumor therapy than the low 
frequency and avidity T cell responses induced by the 
tumor itself. SCIB1 therapy was associated with increased 
infiltration of CD8 T cells within the tumor environment. It 
is known that high avidity T cells infiltrate more efficiently 
into tumors and produce cytokines in response to tumor 
derived antigen [23]. However, the tumor environment 
can promote dysfunction of high avidity T cells with 
reduced IFNγ production and expression of CD107a 
[23, 24]. In this study we have shown that although T 
cell infiltration resulting from SCIB1 DNA vaccination 
demonstrates proliferation and cytokine release it was 
also associated with increased levels of PD-L1 expression 
in the tumor microenvironment. Several published studies 
also indicate that the PD-L1 level within the tumor 
environment can be elevated by infiltrating activated T 
cells secreting IFNγ [25, 26]. The expansion and function 
of infiltrating high avidity T cells induced by vaccination 
could be compromised within the tumor by upregulation 
of PD-1 and engagement with PD-L1 in the melanoma 
tumor microenvironment [26–28]. Upregulation of 
PD-L1 provides another obstacle in the path of vaccine 
induced anti-tumor T cells. Therefore, the combination 
of vaccines with blockade of PD-1/PD-L1 signaling may 
further benefit melanoma patients, especially for late stage 
disease.
PD-1 blockade as a monotherapy also showed 
a significant anti-tumor response and an increased 
infiltration of CD8 but not CD4 T cells. This was likely 
due to stimulation of a different repertoire of T cells to 
the SCIB1 vaccine as PD-1 blockade did not induce T cell 
responses to the TRP2 or gp100 epitopes but did enhance 
responses to the B16 tumor. These responses may be low 
avidity as they failed to secrete IFN-γ or upregulate PD-
L1 expression on the tumor cells. Studies with adoptive 
transfer of low avidity T cells failed to control tumor 
and only when combined with PD-1 blockade resulted 
in tumor regression [23]. In line with these studies most 
vaccines that show synergy with PD-1 blockade have 
not shown regression of established tumors when used 
alone [29–33] and induce low avidity T cells [30]. Their 
results demonstrate that it might be possible to rescue a 
poor vaccine and/or a non-responsive anti-PD-1 tumor 
by using a combination but then the survival is still very 
low. In contrast, our vaccine alone gives good survival 
and anti-PD-1 alone shows therapeutic efficacy in 50% 
of the animals (similar to results in melanoma patients) 
but the combination gives an overall survival of 80%. We 
show additive rather than synergistic responses in the anti-
tumor responses as it would take very large numbers of 
animals to show synergy. We do show synergy with T cell 
infiltration.
We have demonstrated that the combination of 
vaccination to induce high avidity tumor specific T cell 
responses and PD-1 blockade synergises to provide 
tumor therapy and 85% survival in the aggressive B16 
melanoma model. Our previous studies have shown that 
high avidity CTLs fail to proliferate and express high 
levels of PD-1 after supraoptimal TCR stimulation in 
the absence of inflammatory signals [20]. In this study 
we show that the combination of SCIB1 vaccination to 
induce high avidity T cells and PD-1 blockade results in 
a 10 fold increase in infiltration of CD8 T cells due to 
enhanced proliferation at the tumor site. Data from several 
studies in different types of cancer have demonstrated 
that marked infiltration of tumors by immune cells is an 
independent indicator of good prognosis [34–36]. Anti-
PD-1 therapy is known for its localized effect. Analysis of 
immune responses during PD-1 therapy in clinical trials 
indicates that the enhancement of T cell function occurs 
at the tumor site [37]. Our data also suggests that addition 
of PD-1 blockade to the vaccine is more likely to recover 
both the vaccine induced and pre-existing responses at 
tumor site.
In this study we show that SCIB1 and PD-1 
blockade are additive resulting in long term survival in 
80% of animals. This additive effect of ImmunoBody 
vaccine and anti-PD-1 antibody is not restricted to these 
epitopes or DR4 transgenic mice as we have shown similar 
results with an ImmunoBody targeting NY-ESO-1 in 
HLA-A2 transgenic mice [38]. We have shown clinical 
responses in patients receiving SCIB1 treatment alone 
[19]. Equally melanoma patients receiving anti-PD-1/PD-
L1 therapy show response rates of 20-30%. This study 
would suggest that the combination of SCIB1 and anti-
PD-1 should improve this response rate. A new clinical 
study is being planned. In particular we show that SCIB1 
induced IFNγ responses upregulated PD-L1 within the 
tumor thereby reducing the effectiveness of the vaccine. 
Studies in lung cancer patients have suggested that anti-
PD-1 therapy is more effective in patients whose tumors 
express high levels of PD-L1 [9]. Thus any vaccine that 
induces high avidity T cell responses that secrete IFNy 
within the tumor environment may be expected to show 
similar additive effects in combination with anti-PD-1 
therapy.
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MATERIALS AND METHODS
Cell lines and media
B16F1 line was obtained from the ATCC and 
maintained in RPMI with 10% FBS. B16F1-DR4 line was 
obtained as previously described [39]. Media used for 
splenocyte culture was RPMI-1640 with 10% fetal bovine 
serum (FBS), 2mM glutamine, 20mM HEPES buffer, 100 
units/ml penicillin, 100μg/ml streptomycin (complete 
media) and 10-5 M 2-mercaptoethanol.
Reagents
RPMI-1640, FBS, phosphate buffered saline 
(PBS), penicillin-streptomycin, HEPES, glutamine, 
2-mercaptoethanol, collagenase, DNAase and hygromycin 
B were obtained from Sigma (Poole, UK). Fluorochrome 
conjugated antibodies targeting CD4 (APC eFluor 780, 
clone RM4-5), CD3 (PE or PE Cy7, clone 145-2C11), 
Foxp3 (eFluor 450, clone FJK-16s), Ki67 (FITC, clone 
SolA15), CD45 (FITC or eFluor 450, clone 30-F11), PD-
L1 (PE, clone MIH5), CD3 Ab (purified, clone 17A2), 
CD11b (APC-eFluor 780, clone M1/70), GR1 (FITC, 
clone RB6-8C5) were obtained from eBiosciences (San 
Diego, USA). PE-Alexa-647 labeled antibody targeting 
CD8 (clone KT15) was obtained from AbD Serotec 
(Oxford, UK). Anti-PD-1 Ab (clone RMP1-14) was 
obtained from BioXcell (West Lebanon, USA). Synthetic 
peptides TRP2180-188 (SYVDFFVWL) and gp10044-59 
(WNRQLYPEWTEAQRLD) were obtained at > 90% 
purity from Genscript (Piscataway, USA).
Plasmids
SCIB1 is a plasmid encoding a human IgG1 
antibody molecule into which engineered epitopes 
from overexpressed melanoma antigens have been 
inserted. Two HLA*0201 epitopes one from TRP-
2180-188 (SVYDFFVWL) which also is H-2Kb 
restricted (SVYDFFVW) and one from gp100178-186 
(MLGTHTMEV) were inserted alongside a HLA-DR4 
restricted gp10044-59 epitope (WNRQLYPEWTEAQRLD) 
and a gp100174-190 epitope restricted by HLA-DR7, HLA-
DR53 and HLA-DQ6 (TGRAMLGTHTMEVTVYH) into 
the complimentary determining regions of a human IgG1 
expressing plasmid as described previously [17].
Immunization protocol
HLA-DR4 mice (Taconic, USA) were used, aged 
between 8 and 12 weeks, and cared for by the staff at 
Nottingham Trent University. All work was carried out 
under a Home Office approved project license. DNA (1μg/
mouse) was coated onto 1.0μm gold particles (BioRad, 
Hemel Hempstead, UK) using the manufacturer’s 
instructions and administered intradermally by genegun 
(BioRad, USA). Mice were immunized at day 0, 7 and 14 
(unless stated otherwise) and spleens were removed for 
analysis at day 20.
For tumor challenge experiments mice were 
challenged with 2.5x104 or 1.5x105 B16F1-DR4 cells 
subcutaneously on the right flank on day 0 and then 
were immunized with SCIB1 bullets via genegun i.d. 
on days 3, 7 and 10. Anti-PD-1 antibody (250μg/dose) 
was administered i.p. in saline at days 3 and 10. Tumor 
growth was monitored at 3-4 days intervals and mice 
were humanely euthanized once tumor reached ≥10 mm 
in diameter. 200μg/mouse fingolimod (FTY720, Enzo, 
Exeter, UK) were administrated via intraperitoneal (i.p.) 
injection 4 hours prior to immunization on days 3, 7, 10 
and 14.
Elispot assay
Elispot assays were performed using murine 
IFNγ capture and detection reagents according to the 
manufacturer’s instructions (Mabtech, Sweden). In 
brief, anti- IFNγ antibody was coated onto wells of 96-
well Immobilin-P plate. Synthetic peptides (at a variety 
of concentrations) and 5x105 per well splenocytes were 
added to the wells of the plate in triplicate. Plates were 
incubated for 40hrs at 37°C. After incubation, captured 
IFNγ was detected by biotinylated anti- IFNγ antibody and 
developed with a strepatavidin alkaline phosphatase and 
chromogenic substrate. Functional avidity was calculated 
as the concentration mediating 50% maximal effector 
function using a graph of effector function versus peptide 
concentration.
Tumor infiltrate analysis
Tumors were harvested, mechanically disaggregated 
and digested with 1mg/ml collagenase and 100 μg/ml 
DNase and incubated for 30 minutes (Sigma, USA). Cells 
were stained with antibodies targeting cell surface and 
intracellular antigens.
For functional infiltrate analysis tumors were 
mechanically disaggregated and passed through a 0.4μM 
cell strainer (Falcon, UK). Remaining cells were counted 
and plated into 96 well plates previously coated with 
anti-CD3 antibody (eBioscience, USA). Plates were 
incubated for 20hrs and supernatant assessed for IFNγ 
release by ELISA using kits from Mabtech according to 
manufacturer’s instructions.
Statistics
Comparative analysis of the Elispot, flow cytometry 
and tumor volumes data was performed by applying the 
student’s t-test with values of p calculated accordingly. 
Comparison of avidity curves was performed by applying 
two-way ANOVA and survival analysis by applying the 
Log-rank test using Graphpad Prism software.
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